Bifidobacterium Cell Extracts Modulate Monocytes for Infection Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective means to rapidly and effectively prevent and treat viral, bacterial, fungal, or protozoan diseases, as well as inflammatory processes triggered by external pathogenic agents, which can lead to infections, and there is a need to modulate monocyte/macrophage subpopulations for enhanced immune defense.
Innovation Solution
A composition comprising probiotic bacterial strains from the genus Bifidobacterium and/or their cell extracts, which are immunostimulating, anti-inflammatory, and antioxidant, capable of modulating CD16- and CD16+ monocyte subpopulations, thereby regulating their function in inflammatory diseases and infections, using a method that includes the extraction of peptidoglycans from Bifidobacterium strains like B. longum, B. breve, and B. animalis subsp. lactis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used to treat viral, bacterial, fungal, or protozoan diseases, then treatment options are limited, but the effectiveness and speed of treatment are insufficient
Solution Approach 1:
The patent extracts the active immunostimulating components (peptidoglycans, cell wall components) from the probiotic bacteria Bifidobacterium animalis subsp. lactis, creating a concentrated composition that delivers immune-modulating effects rapidly without requiring live bacterial colonization. This extraction allows the active principles to be delivered directly to modulate monocyte/macrophage populations quickly.
Solution Approach 2:
The probiotic composition acts as an intermediary substance that bridges the gap between pathogen exposure and immune response. It contains specific bacterial components (peptidoglycans, lipoteichoic acids) that serve as mediators to activate and modulate the innate immune system, particularly monocyte/macrophage subpopulations, providing a bridge between non-specific and specific immune responses.
2Object-affected harmful factors
If inflammation is suppressed to treat inflammatory diseases, then inflammatory processes are reduced, but immune defense against pathogens is weakened
Solution Approach 1:
The probiotic composition dynamically modulates the immune response rather than statically suppressing or activating it. It contains components that can adaptively regulate monocyte/macrophage polarization, allowing the immune system to respond appropriately to different threats - promoting anti-inflammatory M2 phenotypes during chronic inflammation while maintaining capacity for pro-inflammatory M1 responses against acute pathogens.
Solution Approach 2:
The invention changes the parameters of immune cell function rather than simply increasing or decreasing overall immune activity. It specifically modulates the polarization state, activation level, and functional phenotype of monocyte/macrophage subpopulations, altering multiple immune parameters simultaneously to achieve balanced regulation - reducing harmful inflammation while preserving protective immunity.
3Reliability
If probiotic bacteria are administered to modulate monocyte/macrophage populations, then immune function is enhanced, but the complexity of the therapy increases
Solution Approach 1:
The patent extracts the essential immunostimulating components from the complex probiotic bacteria, isolating peptidoglycans, cell wall components, and other active principles. This simplification maintains the immune-modulating efficacy while reducing the complexity of administering live bacteria, which require specific storage conditions and may have variable effects depending on bacterial viability and strain characteristics.
Solution Approach 2:
The invention changes the form of the probiotic intervention from live bacterial cells to a standardized composition of extracted bacterial components. This parameter change simplifies the therapy by eliminating variables related to bacterial viability, strain variability, and storage requirements, while maintaining the core immunomodulating effects on monocyte/macrophage populations.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to probiotic bacterial strains belonging to the genus Bifidobacterium and/or probiotic cell extracts (PCEs) thereof, having immunostimulating, anti-inflammatory and antioxidant properties. Furthermore, the present invention relates to a composition comprising a mixture comprising or, alternatively, consisting of said probiotic bacterial strains belonging to the genus Bifidobacterium and/or probiotic cell extracts (PCEs) thereof, having immunostimulating, anti-inflammatory and antioxidant properties. Finally, the present invention relates to said composition for use in the preventive and/or curative treatment of (i) inflammatory diseases, (ii) viral, bacterial, fungal or protozoan diseases, (iii) infections, and (iv) flu, cold or fever.